Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. 2002

Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
Department of Laboratory Sciences, School of Health Sciences, Faculty of Medicine, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.

The modifying effect of dietary administration of a polyphenolic antioxidant flavonoid silymarin isolated milk thistle [Silybum marianum (L.) Gaertneri] on 4-nitroquinoline 1-oxide (4-NQO)-induced tongue tumorigenesis was investigated in male F344 rats. Based on the results in pilot studies showing that silymarin treatment together with 4-NQO significantly reduced the occurrence of tongue dysplasia and gavaged with silymarin significantly elevated the phase II detoxifying enzymes' activities in the liver and tongue, the effects of dietary feeding of silymarin on tongue carcinogenesis were investigated in a long-term experiment, where rats were initiated with 4-NQO and fed silymarin containing diets during or after 4-NQO exposure. At 5 weeks of age, all animals except those treated with silymarin alone and untreated rats were given 20 p.p.m. 4-NQO in drinking water for 8 weeks to induce tongue neoplasms. Starting 1 week before 4-NQO administration, animals were fed the experimental diets containing silymarin (100 and 500 p.p.m.) for 10 weeks, and then maintained on a basal diet for 24 weeks. Starting 1 week after the cessation of 4-NQO exposure, the experimental groups given 4-NQO and a basal diet were fed the experimental diets containing 100 or 500 p.p.m. silymarin for 24 weeks. At week 34, feeding of 500 p.p.m. silymarin during the promotion phase significantly inhibited the incidence of tongue carcinoma, when compared with 4-NQO alone group (20% versus 64%, P = 0.019). Dietary silymarin decreased the cell proliferating activity and increased apoptotic index of tongue carcinoma. The treatment with silymarin decreased the polyamine content and prostaglandin (PG) E(2) level in the tongue mucosa. Thus, the results indicate that feeding of silymarin (500 p.p.m.) during the promotion phase of 4-NQO-induced rat tumorigenesis exerts chemopreventive ability against tongue squamous cell carcinoma through modification of phase II enzymes activity, cell proliferation, and/or PGE(2) content.

UI MeSH Term Description Entries
D008297 Male Males
D011073 Polyamines Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. Polyamine
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D004336 Drug Antagonism Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy. Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms
D005980 Glutathione Reductase Catalyzes the oxidation of GLUTATHIONE to GLUTATHIONE DISULFIDE in the presence of NADP+. Deficiency in the enzyme is associated with HEMOLYTIC ANEMIA. Formerly listed as EC 1.6.4.2. Glutathione-Disulfide Reductase,Reductase, Glutathione,Reductase, Glutathione-Disulfide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012838 Silymarin A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent. Carsil,Karsil,Legalon,Silimarin

Related Publications

Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
January 2000, Japanese journal of cancer research : Gann,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
April 2005, Cancer letters,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
July 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
April 2011, Carcinogenesis,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
August 2002, Carcinogenesis,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
June 2001, Fitoterapia,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
February 1991, Carcinogenesis,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
February 2010, Oncology reports,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
July 2009, Oral oncology,
Yoshitame Yanaida, and Hiroyuki Kohno, and Koujiro Yoshida, and Yoshinobu Hirose, and Yasuhiro Yamada, and Hideki Mori, and Takuji Tanaka
January 2015, International journal of clinical and experimental pathology,
Copied contents to your clipboard!